GENEVA, SWITZERLAND--(Marketwire - July 28, 2008) - Addex Pharmaceuticals (SWX: ADXN) released today financial results for the first half of 2008 and gave an update on the status of its lead product, ADX10059, which is in development for GERD (gastroesophageal reflux disease) and migraine.
